Minnesota House Bill HF2230

Minnesota 2025-2026 Regular Session

• Introduced: 3/12/25
• Refer: 3/12/25

Caption

All pharmacies required to make ivermectin and hydroxychloroquine available without a prescription.

Summary

HF2230 would require every registered pharmacy or licensed pharmacist in Minnesota to offer ivermectin and hydroxychloroquine tablets suitable for human use as over-the-counter drugs, meaning they could be sold without a prescription. The bill adds a new statutory definition of “over-the-counter drug” in Minnesota Statutes section 151.01 and creates a new section in chapter 151 directing pharmacies to make these two drugs available for retail sale notwithstanding any contrary law. In practical terms, the bill would change pharmacy dispensing rules for these medications by removing the prescription requirement for their sale, while still limiting the measure to tablets suitable for human use. It would affect pharmacies, pharmacists, patients seeking access to these drugs, and the state’s regulation of prescription-only medications under Minnesota’s pharmacy and drug laws.

Impact

The bill would amend Minnesota Statutes 2024, section 151.01, by adding a definition of “over-the-counter drug” and would add a new section, 151.411, to chapter 151. This would create a statutory mandate that pharmacies and pharmacists offer ivermectin and hydroxychloroquine for over-the-counter sale, overriding any conflicting state law or practice that currently requires a prescription for these drugs. The measure would directly affect pharmacy operations, drug dispensing standards, and the legal status of these medications in Minnesota.

Sentiment

Based on the bill text and available context, the bill appears to be introduced in a straightforward, directive manner with no recorded committee testimony, votes, or amendments in the provided materials. The authorship by multiple House members suggests some legislative support, but there is no documented public debate here to indicate broader consensus or opposition. Overall, the available record shows a neutral procedural posture rather than a clearly established sentiment from committee discussion.

Contention

The main point of contention is likely the policy choice to require pharmacies to sell ivermectin and hydroxychloroquine without a prescription, which departs from standard prescription controls for medications that are typically regulated based on medical oversight. Supporters would likely frame the bill as expanding access and consumer choice, while opponents may raise concerns about safety, appropriate medical use, and the role of pharmacists and physicians in dispensing these drugs. Because no committee transcript or vote record is provided, the specific arguments and which legislators or stakeholders hold them are not documented in the available materials.